Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61

por Wysham, Carol H., Kirkman, M. Sue
Publicado 2011

Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice

por Wysham, Carol H, Kruger, Davida F
Publicado 2021

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like...

por Wysham, Carol H., Campos, Carlos, Kruger, Davida
Publicado 2018

Impact on Knowledge, Competence, and Performance of a Faculty-Led Web-Based Educational Activity for Type 2 Diabetes and Obesity: Questionnaire Study Among Health Care Professional...

por Okemah, Jennifer, Neunie, Sola, Noble, Alexander, Wysham, Carol
Publicado 2023

PSUN326 An Interim Analysis of Healthcare Professionals’ Gaps in Incretin Knowledge Before and After Education

por Brechtelsbauer, Erika L, Black, Robin L, Wysham, Carol Hatch
Publicado 2022

The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis

por Lucero, Katie Stringer, Larkin, Amy, Zakharkin, Stanislav, Wysham, Carol, Anderson, John
Publicado 2023

Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals

por LaRue, Susan, Springer, Jane, Noderer, Michael, Meehan, James, Wysham, Carol H.
Publicado 2018

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective

por De Block, Christophe, Bailey, Clifford, Wysham, Carol, Hemmingway, Andrea, Allen, Sheryl Elaine, Peleshok, Jennifer
Publicado 2022

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes

por Wysham, Carol H., Rosenstock, Julio, Vetter, Marion L., Dong, Fang, Öhman, Peter, Iqbal, Nayyar
Publicado 2017

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week...

por Wysham, Carol H, Rosenstock, Julio, Vetter, Marion L, Wang, Hui, Hardy, Elise, Iqbal, Nayyar
Publicado 2020

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL

por Philis‐Tsimikas, Athena, Lane, Wendy, Pedersen‐Bjergaard, Ulrik, Wysham, Carol, Bardtrum, Lars, Harring, Signe, Heller, Simon
Publicado 2020

OR14-3 The Association of Glycemic Control and Glycemic Variability with Treatment Patterns and Diabetes-Related Events in the Adult Patients (Pts) with Type 1 Diabetes (T1D): Resu...

por Wysham, Carol, Preblick, Ronald, Zhou, Fang Liz, Davies, Michael, Paranjape, Sachin, Sansgiry, Sujit, Xu, Qingqing, Joish, Vijay
Publicado 2019

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2

por Heller, Simon R., DeVries, J. Hans, Wysham, Carol, Hansen, Charlotte T., Hansen, Melissa V., Frier, Brian M.
Publicado 2019

A post‐hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in individuals with...

por Bolli, Geremia B., Wysham, Carol, Fisher, Miles, Chevalier, Soazig, Cali, Anna M. G., Leroy, Bruno, Riddle, Matthew C.
Publicado 2018

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial

por Chaykin, Louis, Bhargava, Anuj, de la Rosa, Raymond, Wysham, Carol H., Nørgård Troelsen, Lone, Østoft, Signe H., Philis-Tsimikas, Athena
Publicado 2019

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program

por Matthews, David R., Wysham, Carol, Davies, Melanie, Slee, April, Alba, Maria, Lee, Mary, Perkovic, Vlado, Mahaffey, Kenneth W., Neal, Bruce
Publicado 2020

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score...

por Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.
Publicado 2019

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

por Wysham, Carol H., Lefebvre, Patrick, Pilon, Dominic, Ingham, Mike, Lafeuille, Marie-Hélène, Emond, Bruno, Kamstra, Rhiannon, Chow, Wing, Pfeifer, Michael, Duh, Mei Sheng
Publicado 2017

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (ED...

por Roussel, Ronan, d'Emden, Michael C., Fisher, Miles, Ampudia‐Blasco, F. Javier, Stella, Peter, Bizet, Florence, Cali, Anna M. G., Wysham, Carol H.
Publicado 2017

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across...

por Wysham, Carol, Bonadonna, Riccardo C., Aroda, Vanita R., Puig Domingo, Manuel, Kapitza, Christoph, Stager, William, Yu, Christine, Niemoeller, Elisabeth, Souhami, Elisabeth, Bergenstal, Richard M.
Publicado 2017